Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Durham, North Carolina

This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1196
Shown on this page
12
Current sort
Recently updated
Location scope
Durham, NC
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Durham, North Carolina. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 373–384 of 1,196 matching trials in Durham, NC.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Durham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional Results available

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851
View directory record Official record
Conditions
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
680
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Pregnancy And Neonatal Health (SPAN)

NCT05515744
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Childbirth
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Completed Phase 3 Interventional

Open-label Trial in Parkinson's Disease (PD)

NCT04760769
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

NCT05172024
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
15,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Completed Not applicable Interventional Results available

Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia

NCT04390750
View directory record Official record
Conditions
Mild Dementia
Interventions
Care Partner-Assisted Intervention
Behavioral
Lead sponsor
New York University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Active, not recruiting Phase 2 Interventional

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT04625647
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Sotorasib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
828
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Completed Phase 2 Interventional Results available

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
55
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Active, not recruiting Phase 2 Interventional

Evolutionary Therapy for Rhabdomyosarcoma

NCT04388839
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide Pill
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 7, 2026, 12:30 AM EST
Completed Phase 1 Interventional

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

NCT01279538
View directory record Official record
Conditions
Kidney Transplantation
Interventions
bleselumab, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 7, 2026, 12:30 AM EST